Drugs / RP12146
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05002868 | Oct 2021 → Apr 2024 | breast cancer, fallopian tube cancer, peritoneum cancer, small cell lung carcinoma | Rhizen Pharmaceuticals SA | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RP12146 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05002868 ↗ |
| Action | Inhibit | “RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor” NCT05002868 ↗ |
| Route | Oral | “RP12146 will be administered orally daily (QD or BID)” NCT05002868 ↗ |